Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight
Sponsor: Metsera, a wholly owned subsidiary of Pfizer
Summary
This study is designed to test how well MET097, an active drug, works to treat individuals with obesity or overweight when compared to placebo. MET097 or placebo will be given to individuals weekly for 28 weeks. If an individual is assigned to MET097 they will receive one of four different dose levels. Participants who have completed the first 28 weeks may participate in an exploratory extension study.
Official title: A Phase 2b, Multi-Center, Randomized, Placebo-Controlled Double-Blind Study to Investigate the Safety and Efficacy of Once-Weekly MET097 in Participants With Obesity and Overweight (VESPER-1)
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
225
Start Date
2024-10-24
Completion Date
2026-05
Last Updated
2026-02-17
Healthy Volunteers
No
Conditions
Interventions
MET097
MET097 is an ultra-long-acting, fully-biased analog of human GLP-1.
Placebo
Sterile 0.9% (w/v) saline will be used as placebo treatment during the study.
Locations (2)
Research Site MET097 24-201-001
Anaheim, California, United States
Research Site MET097 24-201-002
Hollywood, Florida, United States